Latest Commercialisation News

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

Blue Star Helium has successfully started helium production at its Pinon Canyon plant, marking a key milestone as it prepares for commercial sales and expansion in 2026.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.

EIT RawMaterials has committed an additional €1.5 million to advance the Finnish Vanadium Recovery Project, reinforcing its role in Europe's critical materials supply chain. This marks the third funding round supporting technical innovation and project financing efforts.

Biotron Limited has closed its non-renounceable rights issue, raising $645,861 to advance its Hepatitis B virus drug development, with a shortfall commitment from Peak Asset Management still pending.

Bass Oil reported a 2% rise in November oil production alongside a new gas sales agreement with Origin Energy, setting the stage for first gas sales in 2026. Indonesian operations also advanced with production enhancements and upcoming drilling plans.

Impact Minerals’ associate Alluminous has teamed up with US battery innovator C4V to fast-track the commercialisation of its HiPurA® high purity alumina for advanced battery applications, marking a key step in its vertically integrated strategy.

HyTerra Limited has unveiled a comprehensive Strategic Plan targeting commercialisation of its Kansas hydrogen project and ambitious expansion across the US and globally. The plan leverages proprietary technology and recent drilling successes to position the company at the forefront of the emerging geologic hydrogen sector.

4DMedical secures Cleveland Clinic as the third major US academic medical centre to adopt its CT – VQ™ respiratory imaging technology, marking rapid commercial traction post-FDA clearance.

Sparc Technologies has achieved a significant commercial milestone with its first sale of ecosparc®, a graphene-based additive for protective coatings, to an Asian coatings company following successful proof-of-concept testing.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

Dotz Nano Limited has raised approximately A$2 million through a private placement, reinforcing its position in the emerging carbon capture market with fresh capital and new investors.